Evidence map›Paper›PMID 40565309›Full record

ReviewInternational journal of molecular sciences2025

Elucidating DNA Damage-Dependent Immune System Activation.

Elisavet Deligianni, Christina Papanikolaou, Evangelos Terpos, Vassilis L Souliotis

Abstract readReview
In one paragraph

Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Antibody-conjugated polymer nanoparticles for brain cancer.Drug delivery and translational research · 2025
    Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elisavet DeligianniInstitute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece.
Christina PapanikolaouInstitute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece.
Evangelos TerposDepartment of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, 115 28 Athens, Greece.ORCID 0000-0001-5133-1422
Vassilis L SouliotisInstitute of Chemical Biology, National Hellenic Research Foundation, 116 35 Athens, Greece.ORCID 0000-0002-2945-1329

Funding

European Union Project 101097094-ELMUMY
6 · The paper itself

Abstract

The DNA-damage response (DDR) network and the immune system are significant mechanisms linked to the normal functioning of living organisms. Extensive observations suggest that agents that damage the DNA can boost immunity in various ways, some of which may be useful for immunotherapeutic applications. Indeed, the immune system can be activated by the DDR network through a number of different mechanisms, such as via (a) an increase in the tumor neoantigen burden, (b) the induction of the stimulator of interferon genes pathway, (c) the triggering of immunogenic cell death, (d) an increase in antigen presentation as a result of the augmented expression of the major histocompatibility complex type I molecule, (e) modification of the cytokine milieu in the tumor microenvironment, and (f) altered expression of the programmed cell death ligand-1. Together, the DDR network may improve the effect of immunostimulatory anticancer agents and provide a basis for devising more efficient treatment strategies, such as combinatorial therapies of DDR targeting drugs and immunomodulators. Here, the molecular mechanisms underlying the immune system's activation by DDR are summarized, along with some of their possible uses in cancer treatment.

Indexed as

DNA DamageImmune SystemNeoplasmsAnimalsHumansImmunotherapyTumor MicroenvironmentDNA-damage response (DDR)immune checkpoint inhibitorimmune systemimmunogenic cell death (ICD)major histocompatibility complex type I (MHC-I)programmed cell death ligand-1 (PD-L1)stimulator of interferon genes (STING)tumor mutational burden (TMB)tumor neoantigen burden (TNB)

Identifiers

PMID40565309
PMCPMC12192923

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.